Patents by Inventor Wouter de Graaff
Wouter de Graaff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10596103Abstract: Described herein is a vaginal ring drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer and a second therapeutic agent, wherein the second therapeutic agent is in solid form.Type: GrantFiled: December 8, 2014Date of Patent: March 24, 2020Assignee: Merek Sharp & Dohme B.V.Inventors: Dennis Aarts, Wouter de Graaff, Johannes Antonius Hendrikus van Laarhoven
-
Patent number: 10413504Abstract: Described herein is an intra-vaginal drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer, wherein the first therapeutic agent is less permeable in the second thermoplastic polymer than the first thermoplastic polymer, and a second therapeutic agent in solid form, wherein the second therapeutic agent is loaded in a portion of the skin.Type: GrantFiled: December 4, 2014Date of Patent: September 17, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Wouter de Graaff, Willy J. H. Verhoeven
-
Publication number: 20160296467Abstract: Described herein is a vaginal ring drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer and a second therapeutic agent, wherein the second therapeutic agent is in solid form.Type: ApplicationFiled: December 8, 2014Publication date: October 13, 2016Inventors: Dennis Aarts, Wouter de Graaff, Johannes Antonius Hendrikus van Laarhoven
-
Patent number: 9345686Abstract: Disclosed is a drug delivery system from which a macrocyclic lactone can be released with a desirable zero order release profile. The system is based on the use of thermoplastic polymers, and particularly of polyethylene vinyl acetate copolymers (EVA). The drug delivery system of the invention comprises a solid non-porous reservoir in which the macrocyclic lactone is contained, preferably in a concentration well above the saturation concentration, and a non-porous skin covering the reservoir not initially loaded with the drug. The system is preferably in the form of a rod, wherein the core and the skin are concentric, and the end surfaces of the rod are not skin-covered.Type: GrantFiled: March 16, 2010Date of Patent: May 24, 2016Assignee: Intervet Inc.Inventors: Wouter De Graaff, Raymond Zeeman, Niels Honcoop
-
Publication number: 20160038430Abstract: The present invention relates to a veterinary zoo-technical drug delivery system (device) for the simultaneous release of two or more active substances, which system releases the active substances in a substantially constant ratio over a prolonged period of time. The drug delivery system can be in different forms, such as e.g. an implant, or a intravaginal device such as a helical coil, a spring or a ring.Type: ApplicationFiled: October 22, 2015Publication date: February 11, 2016Applicant: INTERVET INC.Inventors: Marc-Antoine Driancourt, Wouter De Graaff, Raymond Zeeman
-
Patent number: 9198857Abstract: The present invention relates to a veterinary zoo-technical drug delivery system (device) for the simultaneous release of two or more active substances, which system releases the active substances in a substantially constant ratio over a prolonged period of time. The drug delivery system can be in different forms, such as e.g. an implant, or a intravaginal device such as a helical coil, a spring or a ring.Type: GrantFiled: March 15, 2010Date of Patent: December 1, 2015Assignee: Intervet Inc.Inventors: Wouter De Graaff, Marc-Antoine Driancourt, Raymond Zeeman
-
Publication number: 20150335464Abstract: An intrauterine system for the retention of a biologically active compound within the uterus of a female mammal is formed by a frame defining an interior space for receipt of a deposit of the compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. Retention elements are provided on the frame for retaining the frame within the uterus.Type: ApplicationFiled: August 3, 2015Publication date: November 26, 2015Inventors: Wouter de Graaff, Harm Veenstra, Titia Martine Truce Mulders
-
Publication number: 20150157561Abstract: Described herein is an intra-vaginal drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer, wherein the first therapeutic agent is less permeable in the second thermoplastic polymer than the first thermoplastic polymer, and a second therapeutic agent in solid form, wherein the second therapeutic agent is loaded in a portion of the skin.Type: ApplicationFiled: December 4, 2014Publication date: June 11, 2015Inventors: Wouter de Graaff, Willy J. H. Verhoeven
-
Patent number: 8900615Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.Type: GrantFiled: November 9, 2012Date of Patent: December 2, 2014Assignee: Merck Sharp & Dohme B.V.Inventors: Rudolf Johannes Joseph Groenewegen, Wouter de Graaff
-
Patent number: 8858977Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.Type: GrantFiled: November 9, 2012Date of Patent: October 14, 2014Assignee: Merck Sharp & Dohme B.V.Inventors: Rudolf Johannes Joseph Groenewegen, Wouter de Graaff, Henk Jan Out
-
Publication number: 20140302115Abstract: A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby, if the delivery system consists of one compartment, the compartment comprises (i) a core of a thermoplastic polyethylene vinylacetate copolymer comprising the progestogenic compound, such progestogenic compound being dissolved in the polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25° C., and an estrogenic compound; and (ii) a skin of a thermoplastic polyethylene vinylacetate copolymer covering the core, said skin being permeable for both compounds; if the delivery system consists of more than one compartment, only one compartment comprises (iii) the progestogenic compound, such progestogenic compound being dissolved in a core of a thermoplastic polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25° C.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Wouter de Graaff, Janneke Sophie Groen, Marcus Antonius Bernardus Kruft, Johannes Antonius Hendrikus Van Laarhoven, Herman Vromans, Raymond Zeeman
-
Publication number: 20140296833Abstract: An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal.Type: ApplicationFiled: November 6, 2013Publication date: October 2, 2014Applicant: Merck Sharp & Dohme B.V.Inventors: Wouter de Graaff, Harm Veenstra, Titia Martine Truce Mulders
-
Patent number: 8808744Abstract: A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby, if the delivery system consists of one compartment, the compartment comprises (i) a core of a thermoplastic polyethylene vinylacetate copolymer comprising the progestogenic compound, such progestogenic compound being dissolved in the polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25° C., and an estrogenic compound; and (ii) a skin of a thermoplastic polyethylene vinylacetate copolymer covering the core, said skin being permeable for both compounds; if the delivery system consists of more than one compartment, only one compartment comprises (iii) the progestogenic compound, such progestogenic compound being dissolved in a core of a thermoplastic polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25° C.Type: GrantFiled: June 5, 2013Date of Patent: August 19, 2014Assignee: Merck Sharp & Dohme B.V.Inventors: Wouter de Graaff, Janneke Sophie Groen, Marcus Antonius Bernardus Kruft, Johannes Antonius Hendrikus Van Laarhoven, Herman Vromans, Raymond Zeeman
-
Patent number: 8741329Abstract: The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first (pharmaceutically) active compound and said intermediate layer is loaded with, crystals of the second (pharmaceutically) active compound.Type: GrantFiled: September 19, 2008Date of Patent: June 3, 2014Assignee: Merck Sharp & Dohme B.V.Inventors: Wouter de Graaff, Raymond Zeeman
-
Patent number: 8722037Abstract: The subject invention provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy.Type: GrantFiled: March 14, 2005Date of Patent: May 13, 2014Assignee: Meck Sharp & Dohme B.V.Inventors: Harm Veenstra, Wouter De Graaff
-
Publication number: 20140056962Abstract: The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first (pharmaceutically) active compound and said intermediate layer is loaded with crystals of the second (pharmaceutically) active compound.Type: ApplicationFiled: October 31, 2013Publication date: February 27, 2014Applicant: Merck Sharp & Dohme B.V.Inventors: Wouter de Graaff, Raymond Zeeman
-
Patent number: 8568374Abstract: An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal.Type: GrantFiled: April 29, 2010Date of Patent: October 29, 2013Assignee: Merck Sharp & Dohme B.V.Inventors: Wouter De Graaff, Harm Veenstra, Titia Martine Truce Mulders
-
Publication number: 20130266632Abstract: A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby, if the delivery system consists of one compartment, the compartment comprises (i) a core of a thermoplastic polyethylene vinylacetate copolymer comprising the progestogenic compound, such progestogenic compound being dissolved in the polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25° C., and an estrogenic compound; and (ii) a skin of a thermoplastic polyethylene vinylacetate copolymer covering the core, said skin being permeable for both compounds; if the delivery system consists of more than one compartment, only one compartment comprises (iii) the progestogenic compound, such progestogenic compound being dissolved in a core of a thermoplastic polyethylene vinylacetate copolymer up to a concentration below the saturation level at 25° C.Type: ApplicationFiled: June 5, 2013Publication date: October 10, 2013Inventors: Wouter de Graaff, Janneke Sophie Groen, Marcus Antonius Bemardus Kruft, Johannes Antonius Hendrikus Van Laarhoven, Herman Vromans, Raymond Zeeman
-
Patent number: 8481079Abstract: Disclosed herein is a drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer. Also disclosed are a contraceptive kit or hormone-replacement therapy kit comprising the drug delivery system, and a combination preparation that simultaneously provides contraception and treatment of a sexually transmitted disease comprising the drug delivery system.Type: GrantFiled: March 16, 2005Date of Patent: July 9, 2013Assignee: Merck Sharp & Dohme B.V.Inventors: Wouter De Graaff, Janneke Sophie Groen, Marcus Antonius Bernardus Kruft, Johannes Antonius Hendrikus Van Laarhoven, Herman Vromans, Raymond Zeeman
-
Publication number: 20130014763Abstract: An intrauterine system for the retention of a biologically active compound within the uterus of a female mammal is formed by a frame defining an interior space for receipt of a deposit of the compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. Retention elements are provided on the frame for retaining the frame within the uterus.Type: ApplicationFiled: September 18, 2012Publication date: January 17, 2013Applicant: MSD Oss B.V.Inventors: Wouter de Graaff, Harm Veenstra, Titia Martine Truce Mulders